Table 1.

Characteristics of CCFA Partner’s Crohn’s disease patients by age at baseline

Characteristics	Older (age ≥ 60) (n=636) Median (IQR) or %	Younger (age 18–59) (n=2756) Median (IQR) or %
Age (years)	65 (62–70)	39 (29–50)
Gender (% female)	62.9	74.9
Education (% >high school)	90.9	91.7
Race (%)
Caucasian	97.8	94.5
African American	1.0	1.7
Other	1.2	3.8
Current smoking (% yes)	6.2	7.8
BMI	25.1 (22.2–28.6)	23.9 (21.2–27.9)
Disease duration (years)	31 (13–42)	10 (4–21)
Ever GI surgery (% yes)	65.2	48.1
Ever GI hospitalization (% yes)	81.3	71.4
Number hospitalizations	4 (2–6)	3 (2–6)
Current medications (%)
Biologic Anti-TNF	29.1	44.3
Immunomodulator*	27.6	32.9
Corticosteroids	16.5	16.0
5-ASA&	40.3	33.9
Remission (sCDAI^ <150) (% yes)	64.2	59.7
sCDAI	114 (72–184)	128 (72–198)
SIBDQ**	5.3 (4.5–6)	4.9 (3.9–5.7)

^*Immunomodulator defined as 6-mercaptopurine, azathioprine, or methotrexate

^&5-aminosalicylate

^{^}Short Crohn’s disease activity index

^**Short inflammatory bowel diseases questionnaire